Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis.
about
Role of vasoactive intestinal peptide in osteoarthritisBerberine induces dendritic cell apoptosis and has therapeutic potential for rheumatoid arthritis.Modulatory effects of vasoactive intestinal peptide on intestinal mucosal immunity and microbial community of weaned piglets challenged by an enterotoxigenic Escherichia coli (K88)Vasoactive intestinal peptide increases hepatic transduction and reduces innate immune response following administration of helper-dependent Ad.Biomarkers predicting a need for intensive treatment in patients with early arthritisSPA0355, a thiourea analogue, inhibits inflammatory responses and joint destruction in fibroblast-like synoviocytes and mice with collagen-induced arthritis.Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.Early effects of lipopolysaccharide-induced inflammation on foetal brain development in rat.Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease SeverityClinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease ActivityKinsenoside inhibits the inflammatory mediator release in a type-II collagen induced arthritis mouse model by regulating the T cells responses.Contractile, but not endothelial, dysfunction in early inflammatory arthritis: a possible role for matrix metalloproteinase-9XH-14, a novel danshen methoxybenzo[b]furan derivative, exhibits anti-inflammatory properties in lipopolysaccharide-treated RAW 264.7 cellsTuning inflammation with anti-inflammatory neuropeptides.Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disordersEffects of Nigella sativa oil extract on inflammatory cytokine response and oxidative stress status in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial.Transcriptional and translational plasticity in rodent urinary bladder TRP channels with urinary bladder inflammation, bladder dysfunction, or postnatal maturation.Protected graft copolymer excipient leads to a higher acute maximum tolerated dose and extends residence time of vasoactive intestinal Peptide significantly better than sterically stabilized micelles.Oral phosphatidylcholine pretreatment alleviates the signs of experimental rheumatoid arthritis.Urinary bladder function and somatic sensitivity in vasoactive intestinal polypeptide (VIP)-/- miceExpression of phosphorylated cAMP response element binding protein (p-CREB) in bladder afferent pathways in VIP-/- mice with cyclophosphamide (CYP)-induced cystitis.Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis.Serum levels of vasoactive intestinal peptide as a prognostic marker in early arthritis.VIP and CRF reduce ADAMTS expression and function in osteoarthritis synovial fibroblasts.Treating arthritis by immunomodulation: is there a role for regulatory T cells?Are biological targets the final goal for rheumatoid arthritis therapy?Th17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect.Crosstalk between the brain and bone.VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts.Effect of VIP on the balance between cytokines and master regulators of activated helper T cells.Urokinase plasminogen activator system in synovial fibroblasts from osteoarthritis patients: modulation by inflammatory mediators and neuropeptides.Vasoactive intestinal peptide alleviates osteoarthritis effectively via inhibiting NF-κB signaling pathway.Vasoactive intestinal peptide suppresses macrophage-mediated inflammation by downregulating interleukin-17A expression via PKA- and PKC-dependent pathways.Mapping the CRF-urocortins system in human osteoarthritic and rheumatoid synovial fibroblasts: effect of vasoactive intestinal peptide.Therapeutic efficacy of vasoactive intestinal peptide in escherichia coli lipopolysaccharide-induced experimental periodontitis in rats.VIP modulates IL-22R1 expression and prevents the contribution of rheumatoid synovial fibroblasts to IL-22-mediated joint destruction.The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide, Modulates the Differentiation and Function of Th Subsets in Rheumatoid Arthritis
P2860
Q26739694-FF39A458-8FD6-4692-A37C-499C9ADFA165Q33772722-BCEC85C0-E4E3-4764-8979-ED723E122E96Q34015572-A0C704A4-3650-445D-A020-5E94FBE66833Q34025143-A22DA411-0070-4C13-A558-313AAEE047CBQ34982012-CD4D2154-126D-428E-921B-58859059297FQ35287485-E82D5F2A-DB71-4145-93F8-9E4C4BC15C34Q35295564-EB490005-BFB0-43D6-AC54-5BF9B524A9E5Q35556890-60FCF2FA-ECD8-4E63-A69B-D564313D47B1Q35768646-2A1448E8-1914-4D80-AA49-81350453C85EQ35924965-5EC705A2-4CC5-4DC4-81F0-E4488A72510AQ35936285-133BF85E-0064-45DE-BC2D-45CE915D095BQ36253978-884DC817-A14B-4ACC-BABB-C4BCCD374C57Q36552242-498DC9F2-1828-428E-B8F0-631B5D33EC8FQ36764912-7B081B3F-339A-47A6-B321-DD1DA9B437E4Q36830470-40504B37-77BC-4EE1-9FCF-A3FF218CA719Q36944947-7E438630-E1C9-4401-9A93-99C1CF1C10CFQ37058323-6050C024-CB75-423A-A9B7-A365C9B763CDQ37074087-5E825CAD-AD61-46FC-84CA-A61E8F790C50Q37206933-3F212C29-FC32-4D02-8440-719BD703AC48Q37219681-376099F1-EC57-4F9D-8118-1CBCC3BE0902Q37255021-06B43A8B-9E0B-445A-9F4D-93684E29CA7AQ37360215-69B5C48B-EEDE-40A2-A4E7-E195E1164761Q37445090-BF9D99C7-60AD-431F-BA52-A9B7A1B8238AQ37447842-98CD474A-C9F0-41C8-B41A-7D06CF83FE72Q37750140-28D11C73-9576-4D4D-ACB5-6AB5E13C3E31Q38041208-42B40EE9-95FE-4B88-B3B4-5C72BA09BD4DQ40957920-F7F6F5E4-9978-431A-BFD7-CD757E7EB25CQ42230264-BDC3B3A0-ACE7-4D53-B3D0-216B201B6BB7Q42487146-60A88AB5-E062-42D1-ADDD-5FDE9B9C633CQ43554142-E95F7029-595D-46D9-820C-8A0EF3A11880Q48120538-4E60E784-89C0-4002-95B5-73F254AAB93AQ52655631-1EF8202D-AF7C-4BB1-A411-3B205FD37877Q53516273-1845040B-4074-4988-8FF7-A9C4C33B145CQ54385451-FB02F084-9EE1-4A52-95A3-16C8B4B116D5Q54397909-EDE2C1C1-0075-485F-ACD3-E5A66EDF5DB1Q54569255-F1F02FDF-6E0C-406A-A619-E939F9235610Q58805868-B7127BF2-869F-467F-9E52-41D44FB1E761
P2860
Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Protective effect of vasoactiv ...... model of rheumatoid arthritis
@nl
Protective effect of vasoactiv ...... model of rheumatoid arthritis.
@ast
Protective effect of vasoactiv ...... model of rheumatoid arthritis.
@en
type
label
Protective effect of vasoactiv ...... model of rheumatoid arthritis
@nl
Protective effect of vasoactiv ...... model of rheumatoid arthritis.
@ast
Protective effect of vasoactiv ...... model of rheumatoid arthritis.
@en
prefLabel
Protective effect of vasoactiv ...... model of rheumatoid arthritis
@nl
Protective effect of vasoactiv ...... model of rheumatoid arthritis.
@ast
Protective effect of vasoactiv ...... model of rheumatoid arthritis.
@en
P2093
P2860
P3181
P356
P1476
Protective effect of vasoactiv ...... model of rheumatoid arthritis
@en
P2093
Alicia Arranz
Carmen Martinez
Florencia Rosignoli
Javier Leceta
Rosa P Gomariz
Yasmina Juarranz
P2860
P2888
P304
P3181
P356
10.1186/AR1779
P407
P577
2005-06-23T00:00:00Z
P5875
P6179
1043651999